Enquiries to Ministry of Health 0800 855 066

APPLICATION FOR SUBSIDY BY SPECIAL AUTHORITY

Page 1 **Form SA1743** May 2025

APPLICANT (stamp or sticker acceptable)	PATIENT NHI:	REFERRER Reg No:		
Reg No:	First Names:	First Names:		
Name:	Surname:	Surname:		
Address:	DOB:	Address:		
	Address:			
Fax Number:		Fax Number:		
Initial application — idiopathic thrombocytope Applications only from a haematologist. Approvals Prerequisites(tick boxes where appropriate)				
Patient has had a splenectomy				
Two immunosuppressive therapies have been trialled and failed after therapy of 3 months each (or 1 month for rituximab) and				
Patient has a platelet count of 20,000 to 30,000 platelets per microlitre and has evidence of significant mucocutaneous bleeding				
Patient has a platelet count	Patient has a platelet count of less than or equal to 20,000 platelets per microlitre and has evidence of active bleeding			
Patient has a platelet count	of less than or equal to 10,000 platelets per microlitre			
Initial application — idiopathic thrombocytope Applications only from a haematologist. Approvals Prerequisites(tick box where appropriate) The patient requires eltrombopag treatm	s valid for 6 weeks.			
	on as proparation to spicitostomy			
Initial application — idiopathic thrombocytope Applications only from a haematologist. Approvals Prerequisites(tick boxes where appropriate)				
Patient has a significant and well-	documented contraindication to splenectomy for clinic	al reasons		
	s have been trialled and failed after therapy of 3 mont	hs each (or 1 month for rituximab)		
Patient has immune thromb	ocytopenic purpura* with a platelet count of less than	or equal to 20,000 platelets per microliter		
Patient has immune thromb mucocutaneous bleeding	ocytopenic purpura* with a platelet count of 20,000 to	30,000 platelets per microlitre and significant		
Initial application — severe aplastic anaemia Applications only from a haematologist. Approvals Prerequisites(tick boxes where appropriate)	s valid for 3 months.			
	s have been trialled and failed after therapy of at least	3 months duration		
· ·	anaemia with a platelet count of less than or equal to	20,000 platelets per microliter		
Patient has severe aplastic bleeding	anaemia with a platelet count of 20,000 to 30,000 plat	elets per microlitre and significant mucocutaneous		

I confirm the above details are correct and that in signing this form I understand I may be audited.

Enquiries to Ministry of Health 0800 855 066

APPLICATION FOR SUBSIDY BY SPECIAL AUTHORITY

Page 2 Form SA1743 May 2025

APPL	ICANT (stamp or sticker acceptable)	PATIENT NHI:	REFERRER Reg No:	
Reg N	0:	First Names:	First Names:	
Name	·	Surname:	Surname:	
Addre	SS:	DOB:	Address:	
		Address:		
Fax N	umber:		Fax Number:	
Eltro	mbopag - continued			
Rene	wal — idiopathic thrombocytopenic purpu	ra - post-splenectomy		
Curre	ent approval Number (if known):			
	cations only from a haematologist. Approvals equisites(tick box where appropriate)	valid for 12 months.		
Г	The patient has obtained a response (see	e Note) from treatment during the initial approval or s	wheeler on transport periods and further treatment	
L	is required	e Note, from treatment during the finitial approval of s	subsequent renewal perious and further treatment	
Note:	Response to treatment is defined as a platel	et count of > 30,000 platelets per microlitre.		
Rene	ewal — idiopathic thrombocytopenic purpu	ra contraindicated to splenectomy		
Current approval Number (if known):				
Applications only from a haematologist. Approvals valid for 12 months.				
	equisites(tick boxes where appropriate)			
	The patient's significant contraindic	cation to splenectomy remains		
and The patient has obtained a response from treatment during the initial approval period				
and Patient has maintained a platelet count of at least 50,000 platelets per microlitre on treatment				
	Further treatment with eltrombopa	g is required to maintain response		
	wal — severe aplastic anaemia			
	ent approval Number (if known):			
Applications only from a haematologist. Approvals valid for 12 months.				
Prere	equisites(tick boxes where appropriate)			
	period	se from treatment of at least 20,000 platelets per mid	crolitre above baseline during the initial approval	
	Platelet transfusion independence	for a minimum of 8 weeks during the initial approval	period	

I confirm the above details are correct and that in signing this form I understand I may be audited.